Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
QRxPharma Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'QRxPharma Limited - Product Pipeline Review - 2014', provides an overview of the QRxPharma Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of QRxPharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of QRxPharma Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of QRxPharma Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the QRxPharma Limited's pipeline products Reasons to buy - Evaluate QRxPharma Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of QRxPharma Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the QRxPharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of QRxPharma Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of QRxPharma Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of QRxPharma Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 QRxPharma Limited Snapshot 5 QRxPharma Limited Overview 5 Key Information 5 Key Facts 5 QRxPharma Limited - Research and Development Overview 6 Key Therapeutic Areas 6 QRxPharma Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 QRxPharma Limited - Pipeline Products Glance 12 QRxPharma Limited - Late Stage Pipeline Products 12 Filing rejected/Withdrawn Products/Combination Treatment Modalities 12 Phase III Products/Combination Treatment Modalities 13 QRxPharma Limited - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 QRxPharma Limited - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 QRxPharma Limited - Drug Profiles 16 (morphine + oxycodone) IR 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 (morphine + oxycodone) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 (morphine + oxycodone) CR 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Q-8008 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Q-8009 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 T-9001 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 V-0801 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 QRxPharma Limited - Pipeline Analysis 25 QRxPharma Limited - Pipeline Products by Target 25 QRxPharma Limited - Pipeline Products by Route of Administration 27 QRxPharma Limited - Pipeline Products by Molecule Type 28 QRxPharma Limited - Pipeline Products by Mechanism of Action 29 QRxPharma Limited - Recent Pipeline Updates 30 QRxPharma Limited - Dormant Projects 38 QRxPharma Limited - Company Statement 39 QRxPharma Limited - Locations And Subsidiaries 40 Head Office 40 Other Locations & Subsidiaries 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 42 Disclaimer 42
List of Tables QRxPharma Limited, Key Information 5 QRxPharma Limited, Key Facts 5 QRxPharma Limited - Pipeline by Indication, 2014 8 QRxPharma Limited - Pipeline by Stage of Development, 2014 9 QRxPharma Limited - Monotherapy Products in Pipeline, 2014 10 QRxPharma Limited - Combination Treatment Modalities in Pipeline, 2014 11 QRxPharma Limited - Filing rejected/Withdrawn, 2014 12 QRxPharma Limited - Phase III, 2014 13 QRxPharma Limited - Phase II, 2014 14 QRxPharma Limited - Preclinical, 2014 15 QRxPharma Limited - Pipeline by Target, 2014 26 QRxPharma Limited - Pipeline by Route of Administration, 2014 27 QRxPharma Limited - Pipeline by Molecule Type, 2014 28 QRxPharma Limited - Pipeline Products by Mechanism of Action, 2014 29 QRxPharma Limited - Recent Pipeline Updates, 2014 30 QRxPharma Limited - Dormant Developmental Projects,2014 38 QRxPharma Limited, Subsidiaries 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.